AstraZeneca v. Natco Pharma: LYNPARZA Olaparib Patent Consolidated in NJ
AstraZeneca AB filed suit in the District of New Jersey against Natco Pharma Ltd. asserting US Patent No. 12,178,816 — issued just nine days before filing — over Natco’s generic ANDA for olaparib (LYNPARZA) 100 mg and 150 mg tablets. Within 148 days, the Court consolidated the case with a broader multi-defendant ANDA proceeding (23-cv-796), signalling coordinated pre-trial management across at least four related olaparib suits.
A freshly-issued PARP inhibitor patent triggers coordinated ANDA warfare in New Jersey
On January 9, 2025, AstraZeneca AB filed suit against Natco Pharma Ltd. in the U.S. District Court for the District of New Jersey, asserting infringement of US Patent No. 12,178,816 (the "’816 patent"). The ‘816 patent issued on December 31, 2024 — just nine days before filing — and covers olaparib tablet formulations sold under the brand name LYNPARZA at the 100 mg and 150 mg dosage strengths. Olaparib is a PARP inhibitor approved for multiple oncology indications including BRCA-mutated ovarian, breast, and prostate cancers, representing a commercially significant asset for AstraZeneca.
The case was closed on June 6, 2025 via consolidation rather than a merits disposition. On May 5, 2025, the Court convened a telephone conference to determine whether this action (along with Civil Action Nos. 25-cv-231, 25-cv-233, and 25-cv-234 — three parallel olaparib ANDA suits) should be consolidated, at minimum for pre-trial purposes, with the existing consolidated matter under docket 23-cv-796. The Court proceeded to consolidate, meaning active litigation continues under the lead docket rather than being dismissed.
The 148-day arc from filing to consolidation is consistent with New Jersey’s active ANDA docket management approach, where judges routinely consolidate overlapping Paragraph IV challenges to reduce duplicative discovery. The filing of four new olaparib actions simultaneously — all asserting the ‘816 patent issued days earlier — suggests AstraZeneca pursued a coordinated enforcement strategy targeting multiple generic filers in a single wave. The ultimate merits outcome, claim construction, and any injunctive relief remain unresolved in the public record at this stage.
Filing to Case Consolidated in 148 days
148 days to consolidation — faster than the median ANDA district court lifecycle
Case consolidated: what the transfer to 23-cv-796 means for both parties
Consolidation merges cases — litigation continues, not dismissed
A consolidation order under Federal Rule of Civil Procedure 42(a) combines actions sharing common questions of law or fact. This case was not dismissed on the merits. AstraZeneca’s infringement claims against Natco survive and proceed under the lead docket (23-cv-796). Pre-trial schedules, discovery, and claim construction will be coordinated across all consolidated defendants, typically reducing duplicative motion practice but extending the overall timeline.
Litigation ongoingAstraZeneca gains unified enforcement of the freshly-issued ‘816 patent
Consolidation typically favours the patent holder in multi-defendant ANDA litigation by allowing a single claim construction ruling to bind all generic challengers simultaneously. AstraZeneca can now assert the ‘816 patent — issued December 31, 2024 — against Natco and co-defendants in a single coordinated proceeding, reducing the risk of inconsistent rulings and streamlining its enforcement posture across the LYNPARZA generic entry wave.
Coordinated enforcementNatco faces coordinated discovery alongside multiple co-defendants
For Natco, consolidation means its invalidity and non-infringement positions will be briefed alongside those of other generic challengers. This can reduce individual litigation costs but also limits strategic independence — Natco’s claim construction arguments must align or be distinguished from co-defendants. An adverse claim construction in the lead case would bind Natco. The path to generic market entry for olaparib tablets now runs through the consolidated schedule.
Shared defence riskLYNPARZA market exclusivity window shaped by consolidated outcome
LYNPARZA (olaparib) generated multi-billion dollar annual revenues for AstraZeneca. The consolidated proceeding over the ‘816 patent — a patent issued at end of 2024, likely representing a later-stage lifecycle extension — will determine whether generic entry is delayed further. For oncology product teams and portfolio planners, the consolidated docket signals that the olaparib IP estate remains actively contested with no near-term generic entry certainty.
Generic entry uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AstraZeneca AB | Individual | Pharmaceutical innovator — holder of US12178816B2 covering LYNPARZA (olaparib) tabletsSearch in Eureka ↗ |
| Defendant | Natco Pharma, Ltd. | Company | Indian generic pharmaceutical manufacturer filing ANDA for olaparib 100 mg & 150 mg tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing AstraZeneca ABSearch in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Natco Pharma, Ltd.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Natco Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Court’s May 5, 2025 telephone conference record confirms consolidation of four new olaparib suits — including this action — with the existing multi-defendant matter 23-cv-796. The phrasing ‘at a minimum for pre-trial purposes’ suggests the Court initially contemplated partial consolidation but ultimately closed the individual dockets. This is a procedural disposition: no claim construction, no merits ruling, and no injunctive determination has issued. The substantive question of whether Natco’s ANDA product infringes the ‘816 patent, and whether that patent is valid, remains live in the consolidated proceeding.
US12178816B2 — Olaparib tablet formulations (LYNPARZA 100 mg & 150 mg)
US Patent No. 12,178,816 (Application No. US18/785063) issued on December 31, 2024, covering formulations of olaparib — a poly(ADP-ribose) polymerase (PARP) inhibitor — as administered in LYNPARZA 100 mg and 150 mg tablets. PARP inhibitors exploit DNA repair pathway deficiencies in tumour cells, and LYNPARZA holds FDA approval across multiple BRCA-mutation-associated cancer indications. A patent issued in late 2024 on a drug approved years earlier suggests this is a continuation or formulation patent aimed at extending commercial protection into the 2040s.
For the oncology generics sector, the ‘816 patent represents a late-lifecycle enforcement asset in one of AstraZeneca’s most commercially critical franchises. The simultaneous filing of four ANDA suits on the same patent within days of issuance reflects a deliberate multi-front enforcement strategy. Competitors and generic manufacturers with ANDA filings for olaparib must evaluate whether their formulations design around the specific claims of the ‘816 patent, particularly given that earlier olaparib patents may have distinct claim scope, making the ‘816 an independent infringement risk.
Should you run an FTO against US12178816B2 before launching generic olaparib?
Any generic pharmaceutical manufacturer holding or planning an ANDA for olaparib tablets — particularly at 100 mg and 150 mg dosage strengths — should treat US12178816B2 as a live enforcement risk. AstraZeneca demonstrated within nine days of issuance that it will assert this patent aggressively. R&D and regulatory teams developing olaparib formulations must assess whether their tablet composition, manufacturing process, or delivery mechanism falls within the ‘816 patent’s claims before committing to an at-risk launch strategy.
PatSnap Eureka’s FTO Search Agent can map the full continuation family surrounding US12178816B2, identify granted claims with overlap to your ANDA formulation, and surface prior art that could support an IPR petition or validity challenge. For oncology generics teams navigating multi-patent ANDA litigation landscapes, Eureka provides claim-level landscape analysis across the olaparib IP estate — giving your legal and R&D teams the intelligence needed to assess launch risk before the consolidated proceeding reaches claim construction.
Run a freedom-to-operate analysis on US12178816B2 to assess your product’s exposure
Run FTO in Eureka →Similar PARP inhibitor ANDA patent cases in U.S. district courts
Cases involving Paragraph IV ANDA challenges to olaparib and other PARP inhibitor patents litigated in U.S. district courts, including the District of New Jersey.
What this case signals for the PARP inhibitor and oncology generic IP landscape
AstraZeneca’s simultaneous four-suit enforcement wave on a patent issued days earlier reflects a disciplined late-lifecycle patent strategy worth monitoring.
Late-issue patents filed within days of issuance signal planned enforcement waves
The ‘816 patent issued December 31, 2024; AstraZeneca filed four ANDA suits by January 9, 2025. This nine-day window suggests pre-litigation preparation was complete before issuance — a common tactic for extending exclusivity on blockbuster oncology drugs. IP teams should monitor continuation and divisional filings in the olaparib family for additional enforcement triggers.
NJ District Court consolidation signals active docket management for ANDA cases
New Jersey courts routinely consolidate parallel ANDA actions, which compresses pre-trial timelines and forces generic challengers to coordinate. Companies planning Paragraph IV filings against complex drug patent estates should anticipate consolidation and build litigation budgets accordingly — individual case strategies may need to be adapted to multi-defendant proceedings.
AB v Natco — key questions answered
The case was closed on June 6, 2025 via consolidation. The Court ordered it merged with the multi-defendant matter 23-cv-796 for at least pre-trial purposes. No merits ruling, claim construction, or injunction issued in this individual docket. Litigation over US12178816B2 continues in the consolidated proceeding.
AstraZeneca asserts US Patent No. 12,178,816 (Application No. US18/785063), which issued on December 31, 2024. The patent covers olaparib tablet formulations corresponding to LYNPARZA 100 mg and 150 mg — a PARP inhibitor used in BRCA-mutation-associated oncology indications.
The Court consolidated this case and three other new olaparib suits (25-cv-231, 25-cv-233, and 25-cv-234) with the existing consolidated matter 23-cv-796 because all cases assert the same ‘816 patent against different generic ANDA filers. Consolidation under FRCP 42(a) allows coordinated pre-trial management, reduces duplicative discovery, and ensures consistent claim construction across all defendants.
LYNPARZA is AstraZeneca’s branded PARP inhibitor approved for multiple BRCA-mutated cancers including ovarian, breast, and prostate. As a high-revenue oncology product, it is a target for Paragraph IV ANDA challenges by generic manufacturers seeking to enter the market before patent expiry. Generic filers must certify that listed patents are invalid or not infringed, triggering a 30-month stay and patent litigation.
Consolidation means Natco’s case will proceed under the schedule set by the 23-cv-796 lead docket, which was filed in 2023. Pre-trial coordination with co-defendants may extend timelines compared to a standalone case. Generic entry for olaparib tablets remains blocked pending the consolidated proceeding’s outcome on validity and infringement of US12178816B2, with no confirmed launch date derivable from the public record.
PatSnap Eureka searches patents and litigation data to answer instantly.